What question did this study set out to answer?

To provide evidence-based guidelines for optimising therapies available for inflammatory bowel disease.

DOP124Therapy optimisation in inflammatory bowel disease: An ECCO topical review across biologics and small molecules

View Full Paper

Ask AI

Bookmark

To provide evidence-based guidelines for optimising therapies available for inflammatory bowel disease.
Expert multidisciplinary panel reviewed pharmacokinetics and treatment strategies.
Conducted systematic literature searches and structured discussions.
Developed consensus statements through PICO methodology and iterative group consensus.
Higher trough levels of anti-TNF agents linked to improved outcomes.
Proactive therapeutic drug monitoring (TDM) recommended to reduce immunogenicity.
Adjusted dosing strategies for vedolizumab, ustekinumab, and small molecules showed potential for improving responses.

No takes yet. Share an insight, caveat, or question.

Topical review optimises biologic and small molecule therapy in inflammatory bowel disease, suggesting better outcomes.

Queiroz et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark